ERBB2 and breast cancer: Moreover, DEBBRAH is an ongoing multicohort, phase II study, recruiting pretreated metastatic HER2-positive and HER2-low breast cancer patients with either stable or untreated or progressing brain metastases and/or leptomeningeal carcinomatosis.